Surrozen, Inc./DE Investing Cash Flow
Surrozen, Inc./DE (SRZN) reported Investing Cash Flow of -$139.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Investing Activities
us-gaap:NetCashProvidedByUsedInInvestingActivities · last filed 2026-08-06
- Surrozen, Inc./DE net cash provided by (used in) investing activities for the quarter ending 2026-06-30 was -$19.00K.
- Surrozen, Inc./DE net cash provided by (used in) investing activities for the quarter ending 2026-03-31 was -$120.00K.
- Surrozen, Inc./DE net cash provided by (used in) investing activities for the quarter ending 2025-12-31 was -$59.00K.
- Surrozen, Inc./DE net cash provided by (used in) investing activities for the quarter ending 2025-09-30 was -$24.00K.
- Surrozen, Inc./DE net cash provided by (used in) investing activities for fiscal 2025 was -$128.00K.
- Surrozen, Inc./DE net cash provided by (used in) investing activities for fiscal 2024 was -$26.00K, a 100.05% decline from fiscal 2023.
- Surrozen, Inc./DE net cash provided by (used in) investing activities for fiscal 2023 was $51.72M, a 35.02% increase from fiscal 2022.
- Surrozen, Inc./DE net cash provided by (used in) investing activities for fiscal 2022 was $38.31M.
| Period end | Net Cash Provided by (Used in) Investing Activities 3 month | Net Cash Provided by (Used in) Investing Activities 4 month | Net Cash Provided by (Used in) Investing Activities 6 month | Net Cash Provided by (Used in) Investing Activities 9 month | Net Cash Provided by (Used in) Investing Activities 12 month |
|---|---|---|---|---|---|
| 2026-06-30 | -$19.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | -$139.00K 10-Q · filed 2026-08-06 | -$198.00K derived: sum of 3 quarters · filed 2026-08-06 | -$222.00K derived: sum of 4 quarters · filed 2026-08-06 | |
| 2026-03-31 | -$120.00K 10-Q · filed 2026-05-06 | -$179.00K derived: sum of 2 quarters · filed 2026-05-06 | -$203.00K derived: sum of 3 quarters · filed 2026-05-06 | -$221.00K derived: sum of 4 quarters · filed 2026-08-06 | |
| 2025-12-31 | -$59.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-23 | -$83.00K derived: sum of 2 quarters · filed 2026-03-23 | -$101.00K derived: sum of 3 quarters · filed 2026-08-06 | -$128.00K 10-K · filed 2026-03-23 | |
| 2025-09-30 | -$24.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-07 | -$42.00K derived: sum of 2 quarters · filed 2026-08-06 | -$69.00K 10-Q · filed 2025-11-07 | -$88.00K derived: sum of 4 quarters · filed 2026-08-06 | |
| 2025-06-30 | -$18.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | -$45.00K 10-Q · filed 2026-08-06 | -$64.00K derived: sum of 3 quarters · filed 2026-08-06 | -$64.00K derived: sum of 4 quarters · filed 2026-08-06 | |
| 2025-03-31 | -$27.00K 10-Q · filed 2026-05-06 | -$46.00K derived: sum of 2 quarters · filed 2026-05-06 | -$46.00K derived: sum of 3 quarters · filed 2026-05-06 | -$46.00K derived: sum of 4 quarters · filed 2026-05-06 | |
| 2024-12-31 | -$19.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-23 | -$19.00K derived: sum of 2 quarters · filed 2026-03-23 | -$19.00K derived: sum of 3 quarters · filed 2026-03-23 | -$26.00K 10-K · filed 2026-03-23 | |
| 2024-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-07 | $0.00 derived: sum of 2 quarters · filed 2025-11-07 | -$7.00K 10-Q · filed 2025-11-07 | $9.49M derived: sum of 4 quarters · filed 2025-11-07 | |
| 2024-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-08 | -$7.00K 10-Q · filed 2025-08-08 | $9.49M derived: sum of 3 quarters · filed 2025-08-08 | $17.14M derived: sum of 4 quarters · filed 2025-08-08 | |
| 2024-03-31 | -$7.00K 10-Q · filed 2025-05-09 | $9.49M derived: sum of 2 quarters · filed 2025-05-09 | $17.14M derived: sum of 3 quarters · filed 2025-05-09 | $34.39M derived: sum of 4 quarters · filed 2025-05-09 | |
| 2023-12-31 | $9.50M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-31 | $17.15M derived: sum of 2 quarters · filed 2025-03-31 | $34.40M derived: sum of 3 quarters · filed 2025-03-31 | $51.72M 10-K · filed 2025-03-31 | |
| 2023-09-30 | $7.65M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-06 | $24.89M derived: sum of 2 quarters · filed 2024-11-06 | $42.22M 10-Q · filed 2024-11-06 | $44.14M derived: sum of 4 quarters · filed 2024-11-06 | |
| 2023-06-30 | $17.25M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-12 | $34.58M 10-Q · filed 2024-08-12 | $36.49M derived: sum of 3 quarters · filed 2024-08-12 | $59.32M derived: sum of 4 quarters · filed 2024-08-12 | |
| 2023-03-31 | $17.33M 10-Q · filed 2024-05-08 | $19.24M derived: sum of 2 quarters · filed 2024-05-08 | $42.07M derived: sum of 3 quarters · filed 2024-05-08 | $56.05M derived: sum of 4 quarters · filed 2024-05-08 | |
| 2022-12-31 | $1.91M derived: 10-K 12 month − 10-Q 9 month · filed 2024-04-10 | $24.74M derived: sum of 2 quarters · filed 2024-04-10 | $38.72M derived: sum of 3 quarters · filed 2024-04-10 | $38.31M 10-K · filed 2024-04-10 | |
| 2022-09-30 | $22.83M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-08 | $36.81M derived: sum of 2 quarters · filed 2023-11-08 | $36.40M 10-Q · filed 2023-11-08 | $19.77M derived: sum of 4 quarters · filed 2023-11-08 | |
| 2022-06-30 | $13.98M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-09 | $13.56M 10-Q · filed 2023-08-09 | -$3.06M derived: sum of 3 quarters · filed 2023-08-09 | -$71.34M derived: sum of 4 quarters · filed 2023-08-09 | |
| 2022-03-31 | -$412.00K 10-Q · filed 2023-05-10 | -$17.03M derived: sum of 2 quarters · filed 2023-05-10 | -$85.32M derived: sum of 3 quarters · filed 2023-05-10 | -$76.68M derived: sum of 4 quarters · filed 2023-05-10 | |
| 2021-12-31 | -$16.62M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-31 | -$84.91M derived: sum of 2 quarters · filed 2023-03-31 | -$76.27M derived: sum of 3 quarters · filed 2023-03-31 | -$77.71M 10-K · filed 2023-03-31 | |
| 2021-09-30 | -$68.28M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-14 | -$59.65M derived: sum of 2 quarters · filed 2022-11-14 | -$61.09M 10-Q · filed 2022-11-14 | -$75.75M derived: sum of 4 quarters · filed 2022-11-14 | |
| 2021-06-30 | $8.64M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-11 | $7.20M 10-Q · filed 2022-08-11 | -$7.46M derived: sum of 3 quarters · filed 2022-08-11 | ||
| 2021-03-31 | -$1.44M 10-Q · filed 2022-05-11 | -$16.10M derived: sum of 2 quarters · filed 2022-05-11 | |||
| 2020-12-31 | -$14.66M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-28 | -$92.00M 10-K/A · filed 2021-05-14 | -$15.07M 10-K · filed 2022-03-28 | ||
| 2020-09-30 | -$414.00K 10-Q · filed 2021-11-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 | |
| AGENUS INC (AGEN) | United States | $0.383B | 1.41 |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| C4 Therapeutics, Inc. (CCCC) | United States | $0.373B | -5.65 |
| FENNEC PHARMACEUTICALS INC. (FENC) | United States | $0.371B | -115.85 |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Artiva Biotherapeutics, Inc. (ARTV) | United States | $0.367B | |
| Cabaletta Bio, Inc. (CABA) | United States | $0.365B | -2.81 |
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B |